This is a randomized, open-label, single-dose, two-period, crossover study to assess the food effect on pharmacokinetics (PK) and safety of LY03020 in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
single dose,administered orally for each period
Beijing AnDing Hospital Capital Medical University
Beijing, China
Maximum observed concentration (Cmax) of LPM787000048 in plasma
Time frame: up to Day 12
Area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of LPM787000048 in plasma
Time frame: up to Day 12
Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t) of LPM787000048 in plasma
Time frame: up to Day 12
Time to maximum observed concentration (Tmax) of LPM787000048 in plasma
Time frame: up to Day 12
Apparent terminal elimination half-life (t1/2) of LPM787000048 in plasma
Time frame: up to Day 12
Number of participants with adverse events (AEs).
Time frame: up to Day 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.